Kragelund Charlotte, Kistorp Caroline, Pedersen Frants, Raymond Ilan, Hildebrandt Per
Frederiksberg University Hospital, Frederiksberg, Denmark.
Scand J Clin Lab Invest Suppl. 2005;240:138-42. doi: 10.1080/00365510500236341.
Recently there has been a growing interest in risk assessment of individuals, using biochemical markers of cardiac risk, with an increasing focus on a multi-marker strategy. Natriuretic peptides (BNP and NT-proBNP) are well-established markers of increased risk in the general population and in high-risk groups with hypertension, and coronary heart disease. However, there is at present no indication for routine measurements of natriuretic peptides in the risk assessment of individuals or patients, as there is no evidence for subsequent therapeutic initiatives. Natriuretic peptides are useful when screening for heart failure in symptomatic individuals. However, the use of NT-proBNP screening for risk or left ventricular systolic dysfunction in the general population is still a matter of debate.
最近,利用心脏风险的生化标志物对个体进行风险评估越来越受到关注,并且越来越注重多标志物策略。利钠肽(脑钠肽和N末端脑钠肽原)是普通人群以及高血压和冠心病等高危人群中已被广泛认可的风险增加标志物。然而,目前尚无迹象表明在个体或患者的风险评估中常规测量利钠肽,因为没有证据支持后续的治疗措施。利钠肽在有症状个体的心力衰竭筛查中很有用。然而,在普通人群中使用N末端脑钠肽原进行风险或左心室收缩功能障碍的筛查仍存在争议。